Compare OEC & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OEC | DCTH |
|---|---|---|
| Founded | 1862 | 1988 |
| Country | Luxembourg | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 319.6M | 363.5M |
| IPO Year | 2014 | 2015 |
| Metric | OEC | DCTH |
|---|---|---|
| Price | $7.66 | $10.82 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $6.56 | ★ $22.00 |
| AVG Volume (30 Days) | 420.7K | ★ 454.5K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.11% | N/A |
| EPS Growth | N/A | ★ 107.53 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,806,700,000.00 | N/A |
| Revenue This Year | N/A | $24.54 |
| Revenue Next Year | $2.21 | $33.15 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.35 | $8.12 |
| 52 Week High | $12.10 | $17.34 |
| Indicator | OEC | DCTH |
|---|---|---|
| Relative Strength Index (RSI) | 59.14 | 48.42 |
| Support Level | $5.96 | $10.29 |
| Resistance Level | $8.40 | $11.14 |
| Average True Range (ATR) | 0.36 | 0.52 |
| MACD | 0.03 | -0.10 |
| Stochastic Oscillator | 84.39 | 16.20 |
Orion SA is a manufacturer of carbon black products. Carbon black is a powdered form of carbon used to create the desired physical, electrical, and optical qualities of various materials. The company's operating segments are Specialty Carbon Black and Rubber Carbon Black. It generates maximum revenue from the Rubber Carbon Black segment. The Rubber Carbon Black segment is used in the reinforcement of rubber in tires and mechanical rubber goods. The Specialty Carbon Black segment is used as pigments and performance additives in coatings, polymers, printing, and special applications. Geographically, it derives a majority of its revenue from Germany.
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.